Health & Biotech
Imricor is the global leader in the development and manufacture of MRI compatible devices for performing cardiac ablations. A cardiac ablation is a procedure conducted by an electrophysiologist where a catheter is guided into the heart with the purpose of burning/ablating the tissue responsible for causing the arrythmia (irregular heartbeat).
The cardiac ablation market, which is over US$8bn per year, currently uses X-Ray guidance to identify the location in the heart that requires treatment. X-Ray as an imaging tool has limitations as it does not show the soft tissue of the heart and exposes the patients and physicians to repeated radiation.
Imricor has the only cardiac ablation devices in the world that have been proven to be safe and effective inside the magnetic field generated by an MRI and, after 18 years of research and development, is now commercialising globally with approvals in Europe, the Middle East and soon to be in both Australia (2024) and the US (2025). The technology is protected by over 70 global patents.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: GTG to establish pilot program in US using its geneType Breast Cancer Risk Test
Health & Biotech
‘Overnight success story 18 years in the making’ – Imricor to transform cardiac ablation market
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: New high for ASX as traders hunt bank, tech stocks; but US data tonight is the real test
News
Market Highlights: More records tumble on Wall Street, and key takeaways from ASX earnings season
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Health Stocks: Amplia gets FDA green light to commence trial; Recce study meets all primary endpoints
Health & Biotech
ASX Health Stocks: Lumos, Singular, and Imricor all jump today after deals and approvals
Health & Biotech
FDA submission looms as Artrya’s AI platform aims to capture the huge cardio diseases market
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX plunges as broad based losses follow perfect storm of fears
Health & Biotech
ASX Health Stocks: Arovella to develop a world-first iNKT cell therapy targeting cancers
News
ASX Health Stocks: Bod Science surges 20pc on cannabis trial results; Recce gets Vietnam trade mark
News
Rise and Shine: Everything you need to know before the ASX opens
News
In Case You Missed It: Ionic rare earths and a resources tech stock enjoys the June quarter
Health & Biotech
ASX Health Stocks: Imricor jumps 19pc on ethics approval to commence cardiac arrest study
Health & Biotech